Details of the Drug Combinations

General Information of This Drug (ID: DMGQ1TV)

Drug Name

ASP1941 DMGQ1TV

Synonyms

Ipragliflozin L-proline; 951382-34-6; UNII-M6N3GK48A4; Suglat (TN); Ipragliflozin (L-Proline); M6N3GK48A4; Ipragliflozin L-proline [JAN]; Ipragliflozin L-proline (JAN); Ipragliflozin mixture with proline; DTXSID20241771; EX-A2771; L-Proline compd. with (1S)-1,5-anhydro-1-C-[3-(benzo[b]thien-2-ylmethyl)-4-fluorophenyl]-D-glucitol (1:1); HY-14894A; AKOS027321043; L-Proline, compd. with (1S)-1,5-anhydro-1-C-(3-(benzo(b)thien-2-ylmethyl)-4-fluorophenyl)-D-glucitol (1:1); AK310367; DS-11639; AC-29892; CS-0019749; D10200

Indication

Disease Entry	ICD 11	Status	REF
Liver disease	DB90-BD99	Phase 3	[1]
------------------------------------------------------------------------------------

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

4 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
ASP1941 + Miglitol	DCP0TND	Miglitol	Type 2 Diabetes Mellitus	[2]
ASP1941 + Nateglinide	DCUT7R5	Nateglinide	Type 2 Diabetes Mellitus	[3]
Sitagliptin + ASP1941	DCCZETX	Sitagliptin	Type 2 Diabetes Mellitus	[4]
Metformin + ASP1941	DCL0PNL	Metformin	Type 2 Diabetes Mellitus	[5]
------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT01054092) A Study to Assess the Long-term Safety and Efficacy of ASP1941 in Japanese Diabetic Patients. U.S. National Institutes of Health.
2	ClinicalTrials.gov (NCT01242202) A Study to Assess the Safety and Efficacy of ASP1941 in Combination With -glucosidase Inhibitor in Type 2 Diabetic Patients
3	ClinicalTrials.gov (NCT01316107) A Study to Assess Safety and Efficacy of ASP1941 in Combination With Nateglinide in Type 2 Diabetic Patients
4	ClinicalTrials.gov (NCT02564211) Ipragliflozin Add-on Long-term Study in Japanese Participants With Type 2 Diabetes Mellitus on Sitagliptin (MK-0431J-849)
5	ClinicalTrials.gov (NCT03118713) A Study to Evaluate the Renal Protective Effect (Urine Albumin-to-Creatinine Ratio (UACR)), Efficacy and Safety of Ipragliflozin in Type 2 Diabetes Mellitus Patients With Albuminuria